Cabotegravir

Status – Access to Investigational Cabotegravir for ***treatment*** of HIV-1 infection in adult and adolescents aged 12 and over weighing at least 35kg, viremic with VL >200 copies/ml, with documented resistance or previous failure of NNRTI-based regimen that ***would prohibit the use of rilpivirine long-acting injectable***, who have limited available alternatives and/ or limited treatment options and in a live saving situation. **AVAILABLE in United States ONLY.**

Status – Access to Investigational Cabotegravir for HIV ***prevention*** is **AVAILABLE outside Africa, Australia, Austria, Belgium, Botswana, Brazil, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania Malawi, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United States and Zimbabwe.**

Fostemsavir

Status – Access to investigational fostemsavir (600 mg extended-release tablets) for the treatment of HIV-1 infection for use in combination with other antiretroviral therapies in heavily treatment experienced adults is **AVAILABLE outside of Australia, Belgium, Canada, France, Germany, Greece, Italy, Luxembourg, Spain, United Kingdom and the United States.**

Refer to ClinicalTrials.gov identifier NCT04233047

Dolutegravir Dispersible Tablets

Status – Access to Investigational Dolutegravir Dispersible Tablet formulation is **AVAILABLE Outside of the following countries:**

Angola	**Denmark**	**Kenya**	**Slovenia**
Austria	**Dominican Republic**	**Lesotho**	**South Sudan**
Belgium	**Eswatini**	**Liberia**	**Spain**
Benin	**Ethiopia**	**Malawi**	**Sweden**
Botswana	**Finland**	**Mali**	**Switzerland**
Burundi	**France**	**Mauritius**	**Tanzania**
Cambodia	**Gambia**	**Mozambique**	**Uganda**
Cameroon	**Germany**	**Namibia**	**United Kingdom**
Canada	**Greece**	**Netherlands**	**United States**
Chad	**Guyana**	**Nigeria**	**Venezuela**
Congo	**Haiti**	**Norway**	**Zambia**
Congo (Democratic Republic of)	**Hungary**	**Papua New Guinea**	**Zimbabwe**
Cote D'Ivoire	**India**	**Poland**	
Croatia	**Ireland**	**Serbia**	
Czech Republic	**Israel**	**Slovakia**	

Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least four weeks and weighing at least 3kg.

Triumeq paediatric Dispersible Tablets

Status – Access to Investigational Triumeq paediatric Dispersable Tablet(s) is **AVAILABLE outside of the United States.**

This document is not intended for general use and contains information, which is sensitive, confidential, and restricted. If you are not the authorised recipient you are hereby notified that any use, copying, distribution of this document or its contents is strictly prohibited.